Lilly Forteo "Approvable": Indications, Manufacturing Issues To Be Resolved
Executive Summary
FDA and Lilly are continuing to discuss the appropriate patient populations for the osteoporosis agent Forteo, Lilly CEO Sidney Taurel told analysts Oct. 3.
You may also be interested in...
Lilly Forteo Labeling Talks Last Step Before Approval; GMP Issues Resolved
Lilly completion of Forteo labeling negotiations with FDA is the only remaining hurdle before final approval, following the resolution of manufacturing issues for the osteoporosis agent
Lilly Forteo Labeling Talks Last Step Before Approval; GMP Issues Resolved
Lilly completion of Forteo labeling negotiations with FDA is the only remaining hurdle before final approval, following the resolution of manufacturing issues for the osteoporosis agent
Lilly To Start Phase III Trials in Diabetic Peripheral Neuropathy For LY-333531
Lilly is expanding its Phase III program for the protein kinase C-beta inhibitor LY-333531 to include diabetic peripheral neuropathy